Bukwang Pharmaceutical Co., Ltd. (003000.KS)
KRW 4745.0
(-1.35%)
KRW 4745.0
(-1.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -71.84 Billion KRW | 15.07% |
| 2022 | -84.58 Billion KRW | -4.15% |
| 2021 | -81.21 Billion KRW | -40.65% |
| 2020 | -57.74 Billion KRW | -62.63% |
| 2019 | -35.5 Billion KRW | 64.63% |
| 2018 | -100.39 Billion KRW | -315.59% |
| 2017 | -24.15 Billion KRW | 41.18% |
| 2016 | -41.07 Billion KRW | 39.16% |
| 2015 | -67.51 Billion KRW | 0.19% |
| 2014 | -67.63 Billion KRW | -17.31% |
| 2013 | -57.65 Billion KRW | -549.9% |
| 2012 | -8.87 Billion KRW | 60.08% |
| 2011 | -22.22 Billion KRW | -3466.8% |
| 2010 | -623.13 Million KRW | -113.45% |
| 2009 | 4.63 Billion KRW | -54.42% |
| 2008 | 10.16 Billion KRW | 132.72% |
| 2007 | -31.06 Billion KRW | 16.75% |
| 2006 | -37.31 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -29.53 Billion KRW | 64.37% |
| 2024 Q1 | -82.89 Billion KRW | -15.39% |
| 2023 Q2 | -67.39 Billion KRW | 2.05% |
| 2023 FY | -71.84 Billion KRW | 15.07% |
| 2023 Q4 | -71.84 Billion KRW | -42.23% |
| 2023 Q1 | -68.8 Billion KRW | 18.65% |
| 2023 Q3 | -50.5 Billion KRW | 25.06% |
| 2022 Q3 | -63.59 Billion KRW | 24.7% |
| 2022 Q2 | -84.46 Billion KRW | 4.34% |
| 2022 Q1 | -88.29 Billion KRW | -8.71% |
| 2022 FY | -84.58 Billion KRW | -4.15% |
| 2022 Q4 | -84.58 Billion KRW | -33.0% |
| 2021 Q2 | -60.68 Billion KRW | 14.11% |
| 2021 FY | -81.21 Billion KRW | -40.65% |
| 2021 Q3 | -76.47 Billion KRW | -26.01% |
| 2021 Q4 | -81.21 Billion KRW | -6.2% |
| 2021 Q1 | -70.65 Billion KRW | -22.37% |
| 2020 FY | -57.74 Billion KRW | -62.63% |
| 2020 Q2 | -3.18 Billion KRW | -191.99% |
| 2020 Q3 | -60.17 Billion KRW | -1791.92% |
| 2020 Q4 | -57.74 Billion KRW | 4.03% |
| 2020 Q1 | 3.45 Billion KRW | 109.74% |
| 2019 Q1 | -112.97 Billion KRW | -12.53% |
| 2019 Q4 | -35.5 Billion KRW | 31.39% |
| 2019 FY | -35.5 Billion KRW | 64.63% |
| 2019 Q2 | -49.46 Billion KRW | 56.22% |
| 2019 Q3 | -51.75 Billion KRW | -4.63% |
| 2018 Q1 | -15.97 Billion KRW | 33.86% |
| 2018 FY | -100.39 Billion KRW | -315.59% |
| 2018 Q4 | -100.39 Billion KRW | -3.2% |
| 2018 Q3 | -97.29 Billion KRW | -44.01% |
| 2018 Q2 | -67.55 Billion KRW | -322.79% |
| 2017 Q2 | -27.85 Billion KRW | 16.29% |
| 2017 Q1 | -33.27 Billion KRW | 18.98% |
| 2017 Q4 | -24.15 Billion KRW | 12.06% |
| 2017 FY | -24.15 Billion KRW | 41.18% |
| 2017 Q3 | -27.47 Billion KRW | 1.38% |
| 2016 Q4 | -41.07 Billion KRW | 10.91% |
| 2016 FY | -41.07 Billion KRW | 39.16% |
| 2016 Q1 | -77.57 Billion KRW | -14.91% |
| 2016 Q2 | -47.35 Billion KRW | 38.96% |
| 2016 Q3 | -46.1 Billion KRW | 2.65% |
| 2015 Q1 | -89.48 Billion KRW | -32.31% |
| 2015 FY | -67.51 Billion KRW | 0.19% |
| 2015 Q4 | -67.51 Billion KRW | 6.48% |
| 2015 Q3 | -72.19 Billion KRW | 2.18% |
| 2015 Q2 | -73.8 Billion KRW | 17.53% |
| 2014 Q4 | -67.63 Billion KRW | 18.61% |
| 2014 FY | -67.63 Billion KRW | -17.31% |
| 2014 Q2 | -79.8 Billion KRW | 0.0% |
| 2014 Q3 | -83.1 Billion KRW | -4.14% |
| 2013 Q4 | -57.65 Billion KRW | 0.0% |
| 2013 FY | -57.65 Billion KRW | -549.9% |
| 2013 Q1 | -59.62 Billion KRW | -572.08% |
| 2012 Q4 | -8.87 Billion KRW | 82.79% |
| 2012 Q1 | -29.54 Billion KRW | 0.0% |
| 2012 FY | -8.87 Billion KRW | 60.08% |
| 2012 Q2 | -43.53 Billion KRW | -47.34% |
| 2012 Q3 | -51.54 Billion KRW | -18.41% |
| 2011 FY | -22.22 Billion KRW | -3466.8% |
| 2011 Q3 | -9.38 Billion KRW | -1447.19% |
| 2011 Q1 | -623.13 Million KRW | -104.82% |
| 2011 Q2 | 696.68 Million KRW | 211.8% |
| 2010 Q3 | 7.19 Billion KRW | 3.63% |
| 2010 Q4 | 12.92 Billion KRW | 79.83% |
| 2010 Q2 | 6.93 Billion KRW | 49.79% |
| 2010 Q1 | 4.63 Billion KRW | -41.13% |
| 2010 FY | -623.13 Million KRW | -113.45% |
| 2009 Q4 | 7.86 Billion KRW | -45.21% |
| 2009 Q3 | 14.36 Billion KRW | 102.37% |
| 2009 Q2 | 7.09 Billion KRW | 0.0% |
| 2009 FY | 4.63 Billion KRW | -54.42% |
| 2008 Q4 | 9.8 Billion KRW | 341.46% |
| 2008 Q2 | -20.68 Billion KRW | 0.0% |
| 2008 Q3 | 2.22 Billion KRW | 110.74% |
| 2008 FY | 10.16 Billion KRW | 132.72% |
| 2007 FY | -31.06 Billion KRW | 16.75% |
| 2007 Q2 | -36.58 Billion KRW | 0.0% |
| 2007 Q3 | -31.7 Billion KRW | 13.34% |
| 2007 Q4 | -55.73 Billion KRW | -75.79% |
| 2006 FY | -37.31 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 916.156% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 112.559% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 123.109% |
| HANDOK Inc. | 283.45 Billion KRW | 125.344% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 457.909% |
| Yuhan Corporation | -69.18 Billion KRW | -3.836% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 137.04% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | -1849.098% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 113.872% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | -121.511% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 194.933% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 295.02% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 187.058% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 386.12% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 916.156% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 55.057% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 135.751% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 142.026% |
| JW Holdings Corporation | 480.68 Billion KRW | 114.945% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 143.65% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 61224.176% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 146.537% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 3155.312% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 412.329% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 141.058% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 238.222% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 916.156% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 145.383% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 120.057% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 146.537% |
| Yuhan Corporation | -69.18 Billion KRW | -3.836% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 152.827% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 220.387% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 116.74% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 146.537% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 161.805% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 537.38% |
| CKD Bio Corp. | 143.29 Billion KRW | 150.134% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 161.895% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | -198.566% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | -60.594% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 3155.312% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 116.99% |
| Boryung Corporation | 187.72 Billion KRW | 138.268% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 194.933% |
| JW Lifescience Corporation | 26.09 Billion KRW | 375.348% |